Gapping up
In reaction to strong earnings/guidance:
- IMMR +15% (entered into settlement and license agreement with Samsung), BEST +9.6%, STNE +7.2%, CYBR +6%, CTST +5.2%, BILI +4.3%, IIIV +3%, KRNT +2.8%, RL +2.3%, GDS +2.2%, TTWO +1%, HOLI +1%
Other news:
- ZEAL +9% (successful results in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes)
- ATHX +8.9% (receives Fast Track designation from the FDA for clinical program evaluating MultiStem cell therapy for the treatment of Acute Respiratory Distress Syndrome
- AES +4% (10% owner ValueAct bought ~2.5 mln shares )
- MDR +3.4% (McDermott announced the award of a 'significant' contract by Petrobras (PBR) for engineering, procurement, construction and installation of subsea risers and flowlines for the first phase of the Sepia field)
- PAGS +2.3% (STNE sympathy)
- WETF +2% (CEO bought 75K shares)
- CTL +0.9% (Director Steven Clontz bought 37K shares worth ~$400K)
Analyst comments:
- MNKD +5.7% (initiated with a Buy at BTIG Research)
- KO +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)